$2.53
▲ +$0.02
(+0.80%)
Vol 640K
11
Quality Score
ok
Deep Check
1/5
fail
Rev ✓
NI ✗
>IPO ✗
Mkt Cap
$1.4B
P/E
27.8
ROE
3.4%
Margin
27.3%
D/E
0.00
Beta
1.34
52W
$2–$5
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.01 | $0.00 | $-0.01 |
| Sep 2025 | $0.00 | $0.08 | +$0.08 |
| Jun 2025 | $-0.02 | $-0.10 | $-0.08 |
| Mar 2025 | $0.00 | $0.02 | +$0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $30.3M | $32.3M | $33.5M | $36.3M | $44.5M |
| Net Income | — | $43.7M | $6.1M | -$39.7M | $26.0M | -$1.8M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 1.7% | 1.7% | 1.7% | 1.7% | 3.4% | 3.4% |
| P/E (TTM) | 39.31 | 51.36 | 57.21 | 50.41 | 26.50 | 27.82 |
| Net Margin | -118.7% | 14.2% | 14.2% | 14.2% | 27.3% | 27.3% |
| Gross Margin | 43.4% | 32.7% | 32.7% | 32.7% | 43.4% | 43.4% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 24.65 | 24.65 | 24.65 | 24.65 | 22.45 | 22.45 |
Key Ratios
ROA (TTM)
3.1%
P/S (TTM)
7.59
P/B
0.8
EPS (TTM)
$0.09
CF/Share
$-0.34
Rev Growth 3Y
+16.5%
52W High
$4.66
52W Low
$2.27
$2.27
52-Week Range
$4.66
Financial Health
Free Cash Flow
$9.6M
Net Debt
-$790.3M
Cash
$791.8M
Total Debt
$1.5M
As of Dec 31, 2025
How does CRON compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
CRON valuation vs Pharmaceuticals peers
P/E ratio
27.8
▲
24%
above
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
7.6
▲
53%
above
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
0.8
▼
64%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
CRON profitability vs Pharmaceuticals peers
ROE
3.4%
▲
106%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
27.3%
▲
158%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
43.4%
▼
37%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
3.1%
▲
108%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
CRON financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
22.5
▲
568%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.3
▲
43%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
CRON fundamentals radar
CRON
Peer median
Industry
CRON profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CRON vs peers: key metrics
Latest News
What Is the Jevons Paradox and What Does It Mean for Micron …
Nasdaq · Apr 04
Micron Stock: Buy, Sell, or Hold?
Nasdaq · Apr 03
Why Micron Stock Slumped 18% in March
Nasdaq · Apr 03
Wall Street Tells Investors Its Less Excited About Micron Stock
Yahoo Finance · Apr 01
Analysts Bullish on Micron Technology (MU) Amid Robust AI Demand
Yahoo Finance · Apr 01